A Clinical Trial of HRS-3095 in Patients With Chronic Spontaneous Urticaria
2026年5月22日 更新者:Chengdu Suncadia Medicine Co., Ltd.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of HRS-3095 in Patients With Chronic Spontaneous Urticaria
The study is being conducted to evaluate the efficacy, and safety of HRS-3095 with Chronic Spontaneous in adults, and to explore the reasonable dosage of HRS-3095 for Chronic Spontaneous Urticaria.
研究概览
研究类型
介入性
注册 (估计的)
190
阶段
- 阶段2
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:Yijia Xu
- 电话号码:+86-0518-81220121
- 邮箱:yijia.xu@hengrui.com
学习地点
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200040
- Huashan Hospital Affiliated to Fudan University
-
首席研究员:
- Wenyu Wu
-
接触:
- Wenyu Wu
- 电话号码:+86-021-52887783
- 邮箱:13601983907@139.com
-
-
Zhejiang
-
Hangzhou、Zhejiang、中国、310006
- Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University
-
首席研究员:
- Liming Wu
-
接触:
- Liming Wu
- 电话号码:+86-13750837205
- 邮箱:18957118053@163.com
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
不
描述
Inclusion Criteria:
- Participants must be between 18 and 70 years of age, inclusive, at the time of signing the Informed Consent Form (ICF), with no restriction on gender.
- Participants must have a history of chronic spontaneous urticaria (CSU) with a disease duration of at least 6 months prior to screening.
- Participants must be diagnosed with H1-antihistamine-inadequately-controlled CSU at screening, defined as: having had persistent symptoms of pruritus and wheals for ≥6 weeks prior to screening, despite regular use of second-generation H1-antihistamines during that period.
- At randomization, the UAS7 score must be ≥16 (range: 0-42) and the HSS7 score ≥ 8 (range: 0-21).
- Participants must have been on a stable dose of the specified second-generation H1-antihistamine for at least 3 days prior to the first UAS score at screening.
- Participants must be willing and able to complete logbook entries as required during the study and must have no missing daily UAS scores during the 7 days before randomization.
- Participants must voluntarily sign the Informed Consent Form (ICF) before any study-related procedures, be able to communicate effectively with the investigator, and be willing to strictly adhere to the requirements of the study protocol.
- Female participants of childbearing potential or male participants with a female partner of childbearing potential must agree to avoid donating sperm or ova and must agree to take highly effective contraceptive measures from the time of signing the ICF until 3 months after the last dose.
Exclusion Criteria:
- Any skin disease that could interfere with study assessment (e.g., chronic inducible urticaria, urticarial vasculitis, atopic dermatitis, psoriasis).
- Use of systemic or topical medications with therapeutic or immunomodulatory effects on the study disease during the relevant washout period prior to screening.
- Use of investigational drugs or medical devices within 8 weeks or 5 half-lives (if known), whichever is longer, or within 30 days (for small molecules) prior to screening.
- Vaccination or exposure to live or attenuated vaccines within 3 months prior to screening or participation in a vaccine-related clinical trial within 3 months prior to randomization.
- History or current coagulation-related risk (e.g., bleeding diathesis, coagulopathy, GI bleeding with clinical significance, antiplatelet or anticoagulant use, history of thrombosis or thromboembolic events, or increased risk of thrombosis).
- History of liver disease or current treatment for liver disease (e.g., hepatitis, cirrhosis, liver failure).
- History of systemic antimicrobial use or presence of superficial skin infection (e.g., impetigo) within 4 weeks prior to screening.
- History of malignancy or current malignancy (excluding completely resected and recurrence-free basal cell carcinoma, squamous cell carcinoma, or cervical intraepithelial neoplasia).
- Major surgery performed within 3 months prior to randomization or planned during the study.
- Serious concomitant disease or any condition judged by the investigator to make the participant unsuitable for study participation.
- Abnormal findings in vital signs, physical examination, laboratory tests, ECG, chest X-ray/CT, or abdominal ultrasound during screening that have clinical significance and may affect study validity or participant safety.
- Pregnant or breastfeeding women.
- Allergy to the study drug or any of its components.
- History of alcohol abuse within 6 months prior to screening (e.g., > 14 units/week) or history of illicit drug abuse within 6 months prior to screening.
- Any condition judged by the investigator that may affect the safety or efficacy evaluation of the study drug or participant compliance with the study procedures or diary.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:HRS-3095 Group
HRS-3095 in different doses.
|
HRS-3095 tablet.
|
|
安慰剂比较:HRS-3095 placebo Group
HRS-3095 blank preparation.
|
HRS-3095 tablet placebo.
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Change in Weekly Urticaria Activity Score (UAS7) from baseline at Week 4.
大体时间:Up to 4 weeks.
|
Up to 4 weeks.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
The concentration of HRS-3095 in serum (Cmax)
大体时间:From the beginning of administration to the 4th week.
|
From the beginning of administration to the 4th week.
|
|
|
The time of metabolism of the drug in the serum
大体时间:From the beginning of administration to the 4th week.
|
The concentration of HRS-3095 in plasma will be determined.
|
From the beginning of administration to the 4th week.
|
|
The concentration of HRS-3095 in serum (AUC)
大体时间:From the beginning of administration to the 4th week.
|
The concentration of HRS-3095 in plasma will be determined.
|
From the beginning of administration to the 4th week.
|
|
Change in Weekly Urticaria Activity Score (UAS7) from baseline at Week 2
大体时间:Up to 4 weeks.
|
Up to 4 weeks.
|
|
|
Change in Weekly Itch Severity Score (ISS7) from baseline at Week 2 and 4
大体时间:Up to 4 weeks.
|
Up to 4 weeks.
|
|
|
Change in Weekly Wheal Severity Score (HSS7) from baseline at Week 2 and 4
大体时间:Up to 4 weeks.
|
Up to 4 weeks.
|
|
|
Percentage change in Weekly Urticaria Activity Score (UAS7) from baseline at Week 2 and 4
大体时间:Up to 4 weeks.
|
Up to 4 weeks.
|
|
|
Percentage change in Weekly Itch Severity Score (ISS7) from baseline at Week 2 and 4
大体时间:Up to 4 weeks.
|
Up to 4 weeks.
|
|
|
Percentage change in Weekly Wheal Severity Score (HSS7) from baseline at Week 2 and 4
大体时间:Up to 4 weeks.
|
Up to 4 weeks.
|
|
|
Proportion of patients with UAS7 ≤ 6 at Week 2 and 4 compared to baseline
大体时间:Up to 4 weeks.
|
Up to 4 weeks.
|
|
|
Proportion of patients with UAS7 = 0 at Week 2 and 4 compared to baseline
大体时间:Up to 4 weeks.
|
Up to 4 weeks.
|
|
|
Proportion of patients achieving the Minimum Important Difference (MID) in UAS7 at Week 2 and 4
大体时间:Up to 4 weeks.
|
≥ 10-point decrease from baseline.
|
Up to 4 weeks.
|
|
Proportion of patients achieving the Minimum Important Difference (MID) in ISS7 at Week 2 and 4
大体时间:Up to 4 weeks.
|
≥ 5-point decrease from baseline.
|
Up to 4 weeks.
|
|
Time to achieve the Minimum Important Difference (MID) in UAS7
大体时间:Up to 4 weeks.
|
≥ 10-point decrease from baseline.
|
Up to 4 weeks.
|
|
Time to achieve the Minimum Important Difference (MID) in ISS7
大体时间:Up to 4 weeks.
|
≥ 10-point decrease from baseline.
|
Up to 4 weeks.
|
|
Change in 7-day Angioedema Activity Score (AAS7) from baseline at Week 2 and 4
大体时间:Up to 4 weeks.
|
Up to 4 weeks.
|
|
|
Change in Urticaria Control Test (UCT) from baseline at Week 4
大体时间:Up to 4 weeks.
|
Up to 4 weeks.
|
|
|
Proportion of participants with UCT ≥ 12 at Week 4 compared to baseline
大体时间:Up to 4 weeks.
|
Up to 4 weeks.
|
|
|
Change in Dermatology Life Quality Index (DLQI) from baseline at Week 4
大体时间:Up to 4 weeks.
|
Up to 4 weeks.
|
|
|
Proportion of participants with DLQI = 0 or 1 at Week 4 compared to baseline
大体时间:Up to 4 weeks.
|
Up to 4 weeks.
|
|
|
Adverse events
大体时间:From the beginning of administration to the 8th week.
|
From the beginning of administration to the 8th week.
|
|
|
Plasma concentrations of HRS-3095 and its metabolites
大体时间:From the beginning of administration to the 4th week.
|
From the beginning of administration to the 4th week.
|
|
|
Relative change from baseline in serum total immunoglobulin E (IgE)
大体时间:From the beginning of administration to the 4th week.
|
From the beginning of administration to the 4th week.
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (估计的)
2026年7月1日
初级完成 (估计的)
2026年12月1日
研究完成 (估计的)
2027年3月1日
研究注册日期
首次提交
2026年5月22日
首先提交符合 QC 标准的
2026年5月22日
首次发布 (实际的)
2026年5月29日
研究记录更新
最后更新发布 (实际的)
2026年5月29日
上次提交的符合 QC 标准的更新
2026年5月22日
最后验证
2026年5月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.